Lung Cancer
We recommend
Incidence of Brain Metastases and Intracranial Activity of Sotorasib in Patients with NSCLC with G12C Mutation of the KRAS Oncogene
Sotorasib is the first targeted drug approved for the treatment of metastatic non-small cell lung cancer (NSCLC) with the G12C mutation of the KRAS oncogene. The newly published study presented below investigated its intracranial activity.
Pokroky v léčbě pokročilého NSCLC s mutací G12C onkogenu KRAS
Na mutace onkogenu KRAS, včetně nejběžnější varianty G12C, se dlouho nedařilo cílit léčbu. Nedávný…
Change in Mutation Characteristics of NSCLC Detected by Liquid Biopsy – Case Study
Due to changes in mutations during the progression of metastatic non-small cell lung cancer (NSCLC)…
Articles on this topic
Excellent effect of sotorasib in a higher line of treatment in a patient with NSCLC with G12C mutation of KRAS – a case study
We present a case study of an elderly patient with non-small cell lung cancer (NSCLC) treated…
Inhibition of Mutated KRAS Protein as a New Option for Targeted Treatment of Non-Small Cell Lung Cancer
RAS proteins are molecular switches for several intracellular signaling pathways. Their…
Long-term Benefit of Sotorasib for Survival of Patients with Pre-treated Advanced/Metastatic NSCLC with G12C Mutation of KRAS Oncogene
Sotorasib is indicated as monotherapy for advanced non-small-cell lung cancer (NSCLC) with the…
Sotorasib in the Treatment of a Patient with NSCLC and DIC – A Case Report
Sotorasib is the first clinically used inhibitor of the KRAS oncogene with the G12C mutation.…
Can We Reach Brain Metastases of Lung Cancer with Anti-EGFR Targeted Therapy?
Information on the penetration of epidermal growth factor receptor tyrosine kinase inhibitors…
Diagnosis, Treatment, and Outcomes Achieved in Patients with Non-Small-Cell Lung Cancer in Central Europe
In June 2020, the journal Radiology and Oncology published the results of an analysis of data…
Treatment with Osimertinib in Patients with NSCLC After Disease Progression on Previous Therapy – Case Study
We present a case study of a patient with non-small cell lung cancer (NSCLC) with a proven…
Osimertinib in the Treatment of Patients with NSCLC with Secondary EGFR T790M Mutation – Case Study
Non-small cell lung cancer (NSCLC) is a genetically heterogeneous disease. Individualization…
How to Communicate and Receive an Oncological Diagnosis
Communicating the truth about a patient's health condition does not have a very long tradition...
Patient Evaluation of Durvalumab Treatment Results
The interim analysis results of the PACIFIC study, which monitored the efficacy of durvalumab…
Subscribe
Most read on this topic
- Osimertinib in the Treatment of Patients with NSCLC with Secondary EGFR T790M Mutation – Case Study
- Treatment with Osimertinib in Patients with NSCLC After Disease Progression on Previous Therapy – Case Study
- Can We Reach Brain Metastases of Lung Cancer with Anti-EGFR Targeted Therapy?
- Sotorasib in the Treatment of a Patient with NSCLC and DIC – A Case Report
- Diagnosis, Treatment, and Outcomes Achieved in Patients with Non-Small-Cell Lung Cancer in Central Europe
- Long-term Benefit of Sotorasib for Survival of Patients with Pre-treated Advanced/Metastatic NSCLC with G12C Mutation of KRAS Oncogene
Journal on this topic
Related topic